Clinical Trials Logo

Lymphoma, T-Cell, Cutaneous clinical trials

View clinical trials related to Lymphoma, T-Cell, Cutaneous.

Filter by:

NCT ID: NCT00004241 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma

Start date: October 1999
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with advanced epithelial cancer, malignant lymphoma, or sarcoma

NCT ID: NCT00003970 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma

Start date: January 1999
Phase: Phase 1
Study type: Interventional

Phase I trial to study genetic testing and the effectiveness of irinotecan in treating patients who have solid tumors and lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Genetic testing for a specific enzyme may help doctors determine whether side effects from or response to chemotherapy are related to a person's genetic makeup

NCT ID: NCT00003613 Terminated - Clinical trials for Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Start date: April 1999
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of carmustine given together with O(6)-benzylguanine in treating patients with stage I or stage II cutaneous T-cell lymphoma that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells

NCT ID: NCT00003210 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

Start date: February 1998
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of interleukin-12 in treating patients with previously treated non-Hodgkin's lymphoma or Hodgkin's disease. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill lymphoma cells.

NCT ID: NCT00003196 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma

Start date: September 1997
Phase: N/A
Study type: Interventional

This pilot clinical trial studies low-dose total body irradiation and donor peripheral blood stem cell transplant followed by donor lymphocyte infusion in treatment patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, or multiple myeloma. Giving total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them. Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may boost this effect.

NCT ID: NCT00001249 Completed - Clinical trials for Lymphoma, T-Cell, Cutaneous

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

Start date: December 1989
Phase: Phase 1
Study type: Interventional

The study purpose is to evaluate the clinical response to multidose administration of anti-Tac monoclonal antibody conjugated with 10 mCi 90Y in patients with Tac-expressing adult T-cell leukemia (ATL).